This evidence drove the study of the IDO and TDO pharmacological inhibitors as anti-tumor therapeutic strategies; however, the use of these inhibitors has not been successful in clinical trials for GBM patients [47,48]. This evidence concerns the gene IDO1 and neoplasm.